Article Text

other Versions

Renal tumor suppressor function of the Birt-Hogg-Dube syndrome gene product folliculin
  1. Valerie Hudon1,
  2. Sylvie Sabourin1,
  3. Anders Bondo Dydensborg1,
  4. Vasiliki Kottis1,
  5. Abbas Ghazi1,
  6. Marilene Paquet1,
  7. Kathie Crosby2,
  8. Veronique Pomerleau1,
  9. Norico Uetani1,
  10. Arnim Pause1,*
  1. 1 McGill University, Canada;
  2. 2 Cell Signaling Technologies, Canada
  1. Correspondence to: Arnim Pause, McGill University, 3655 Sir william osler promenade, Montreal, Qh3g1y6, Canada; arnim.pause{at}


Renal cell carcinoma (RCC) comprises five major molecular and histological subtypes. The Birt-Hogg-Dubé (BHD) syndrome is a hereditary human cancer syndrome that predisposes affected individuals to develop renal carcinoma of nearly all subtypes, in addition to benign fibrofolliculomas, pulmonary and renal cysts. BHD is caused by loss-of-function mutations in the FLCN protein. The molecular function of FLCN is still largely unknown; opposite and conflicting evidence of the role of FLCN in mTOR signaling/phospho-S6 (p-S6) activation have recently been reported. Here, we describe the expression pattern of murine Flcn and observe that homozygous disruption of Flcn results in embryonic lethality early during development. Importantly, heterozygous animals manifest early preneoplastic kidney lesions devoid of Flcn expression that progress toward malignancy including cystopapillary adenomas. Bona fide tumor suppressor activity of FLCN was confirmed by nude mouse xenograft assays of two human RCC cell lines with either diminished or re-expressed FLCN. Strikingly, tumor suppression by FLCN was independent of the status of another renal tumor suppressor, the von Hippel-Lindau gene (VHL). We observed that loss of FLCN expression leads to repression or stimulation of S6 activation in a context dependent manner. Indeed, solid tumors and normal kidney show decreased p-S6 upon diminished FLCN expression. Conversely, p-S6 is found to be elevated or absent in FLCN negative renal cysts. In accordance with clinical data showing distinct renal malignancies arising in BHD patients, this study demonstrates that FLCN is a general tumor suppressor in the kidney which operates on a unique and VHL-independent pathway.

Statistics from


    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.